Skip to content

Nurix Therapeutics

US · NRIX #2679 by market cap Listed 2020
12.85 -0.75 -5.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Founded
2009
CEO
Dr. Arthur T. Sands, M.D.,PhD
Employees
317
Headquarters
Brisbane, California, United States of America
Fiscal year end
11-30
Website
nurixtx.com

Company profile

Exchange
US
Symbol
NRIX
Market-cap rank
#2679
Listing date
2020-07-24
Market cap
1.40B
Float cap
1.12B
Shares out
109.25M
Float shares
87.20M

Sectors & themes

Biotechnology ARK Portfolio Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Nurix Therapeutics discussion 0 comments

Add a comment